TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cann Group ( (AU:CAN) ) has shared an announcement.
Cann Group Limited has announced an Extraordinary General Meeting (EGM) scheduled for December 23, 2025, to seek shareholder approval for several resolutions following a major refinancing transaction. This refinancing has significantly reduced the company’s debt from approximately $70 million to $15 million, providing essential funding for working and growth capital. The EGM will address the election of a new director and the approval of various options related to the capital raise, which includes issuing new shares and options to participants, including directors, as part of the company’s strategic financial restructuring.
More about Cann Group
Cann Group Limited is a company focused on enhancing patients’ lives through the development, production, and supply of innovative cannabis medicines. The company has established world-class research, cultivation, and GMP manufacturing facilities in Melbourne and a large-scale facility near Mildura, Victoria. Cann Group offers a variety of dried flower and oil products, active pharmaceutical ingredients, and extracts to customers in Australia and globally. Additionally, it owns Satipharm and its patent-protected capsule technology.
Average Trading Volume: 3,671,943
Technical Sentiment Signal: Sell
Current Market Cap: A$9.13M
For an in-depth examination of CAN stock, go to TipRanks’ Overview page.